Want to see TSE:BLAB full AI Analyst Report?
Top Page
Britannia Life Sciences Inc
(BLAB)
Select Model
Select Model
Rating:47Neutral
Price Target:
C$0.07
▲(15.00% Upside)
Action:Reiterated
Date:08/02/26
The score is primarily constrained by weak financial performance: sharply lower revenue, ongoing operating losses, and negative operating/free cash flow in the last two years, which raises execution and liquidity risk. Technicals are also soft with the stock below key longer-term moving averages. A very low P/E provides some valuation appeal, but it is tempered by concerns that recent earnings are not supported by core operating performance.
Positive Factors
Stronger capital structure
A materially rebuilt equity base and near-elimination of debt meaningfully reduce solvency and refinancing risk. This improved capital structure gives management multi-months of financial flexibility to fund operations or strategic initiatives without immediate reliance on dilutive financing.
Negative Factors
Severe revenue collapse
A multi-year, order-of-magnitude drop in revenue signals underlying commercial or product failures and materially reduces scale economies. Sustained low top-line undermines margin recovery, limits reinvestment capacity and increases dependence on non-operating items or external financing to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger capital structure
A materially rebuilt equity base and near-elimination of debt meaningfully reduce solvency and refinancing risk. This improved capital structure gives management multi-months of financial flexibility to fund operations or strategic initiatives without immediate reliance on dilutive financing.
Read all positive factors
Britannia Life Sciences Inc (BLAB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$10.55M
Dividend YieldN/A
Average Volume (3M)73.07K
Price to Earnings (P/E)0.8
Beta (1Y)-1.18
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.08
Shares Outstanding162,254,330
10 Day Avg. Volume81,691
30 Day Avg. Volume73,070
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.70
Price to Sales (P/S)30.75
P/FCF Ratio-12.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Britannia Life Sciences Inc Business Overview & Revenue Model
Company Description
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics,...
Britannia Life Sciences Inc Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | Jun 2025 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 474.83K | 369.28K | 7.57M | 6.40M | 7.30M |
| Gross Profit | 38.86K | 27.33K | 4.85M | 4.64M | 5.26M |
| EBITDA | -1.39M | -4.39M | -1.90M | 6.95M | -10.77M |
| Net Income | 13.07M | 7.39M | -4.77M | 5.08M | -15.46M |
Balance Sheet | |||||
| Total Assets | 23.87M | 11.61M | 22.26M | 23.55M | 21.09M |
| Cash, Cash Equivalents and Short-Term Investments | 17.14M | 7.85M | 1.32M | 2.60M | 1.63M |
| Total Debt | 229.14K | 1.86M | 7.29M | 8.41M | 5.19M |
| Total Liabilities | 3.12M | 5.31M | 15.59M | 12.49M | 15.61M |
| Stockholders Equity | 20.75M | 6.30M | 2.44M | 7.02M | 1.35M |
Cash Flow | |||||
| Free Cash Flow | -1.16M | -2.62M | 1.75M | 874.41K | 2.71M |
| Operating Cash Flow | -1.16M | -2.62M | 2.09M | 1.22M | 2.80M |
| Investing Cash Flow | -5.25M | 11.27M | -1.44M | -3.32M | 653.95K |
| Financing Cash Flow | -110.77K | -2.17M | -1.97M | 2.95M | -2.58M |
Britannia Life Sciences Inc Technical Analysis
Negative
0.06
Price Trends
0.07
Negative
0.08
Negative
0.09
Negative
Market Momentum
>-0.01
Positive
39.39
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.39 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLAB.
Britannia Life Sciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLAB
Britannia Life Sciences Inc
0.07
-0.02
-23.53%
TSE:HEM
Hemostemix
0.07
-0.02
-23.53%
TSE:IOT
Innovotech
0.09
-0.15
-64.58%
TSE:GLOW
Glow LifeTech
0.05
>-0.01
-10.00%
TSE:TELI
Telescope Innovations Corp
0.43
0.09
26.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.